The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of LENZ Therapeutics Inc (NASDAQ: LENZ) closed at $40.0 in the last session, up 0.38% from day before closing price of $39.85. In other words, the price has increased by $0.38 from its previous closing price. On the day, 0.66 million shares were traded. LENZ stock price reached its highest trading level at $41.26 during the session, while it also had its lowest trading level at $39.27.
Ratios:
We take a closer look at LENZ’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 20.54 and its Current Ratio is at 20.54. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 18, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $60.
On September 27, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $37.Raymond James initiated its Outperform rating on September 27, 2024, with a $37 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 15 ’25 when Versant Venture Capital VI, L. sold 145,051 shares for $39.50 per share. The transaction valued at 5,729,514 led to the insider holds 1,430,848 shares of the business.
Versant Venture Capital VI, L. sold 69,949 shares of LENZ for $2,762,986 on Aug 15 ’25. The 10% Owner now owns 977,963 shares after completing the transaction at $39.50 per share. On Aug 18 ’25, another insider, Versant Venture Capital VI, L., who serves as the 10% Owner of the company, sold 30,628 shares for $38.56 each. As a result, the insider received 1,181,049 and left with 1,400,220 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LENZ now has a Market Capitalization of 1140883968 and an Enterprise Value of 932415872. For the stock, the TTM Price-to-Sale (P/S) ratio is 228.16 while its Price-to-Book (P/B) ratio in mrq is 5.52. Its current Enterprise Value per Revenue stands at 186.483 whereas that against EBITDA is -15.071.
Stock Price History:
The Beta on a monthly basis for LENZ is 0.50, which has changed by 0.8181819 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, LENZ has reached a high of $41.70, while it has fallen to a 52-week low of $16.53. The 50-Day Moving Average of the stock is 21.29%, while the 200-Day Moving Average is calculated to be 38.14%.
Shares Statistics:
According to the various share statistics, LENZ traded on average about 428.62K shares per day over the past 3-months and 885280 shares per day over the past 10 days. A total of 28.50M shares are outstanding, with a floating share count of 23.85M. Insiders hold about 17.28% of the company’s shares, while institutions hold 92.20% stake in the company. Shares short for LENZ as of 1753920000 were 3822202 with a Short Ratio of 8.92, compared to 1751241600 on 3668552. Therefore, it implies a Short% of Shares Outstanding of 3822202 and a Short% of Float of 24.82.
Earnings Estimates
Its stock is currently analyzed by 5.0 different market analysts. The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.63 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.19 and -$2.75 for the fiscal current year, implying an average EPS of -$2.56. EPS for the following year is -$2.5, with 6.0 analysts recommending between -$1.75 and -$3.65.
